Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.

Vertex is expanding beyond its cystic fibrosis franchise.

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

This biotech player is firing on all cylinders.

Management expects both CASGEVY and JOURNAVX to become multibillion-dollar assets. If those drugs slowed, a holder would ...

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney ...

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

Vertex, Inc. (VERX) unveils Vertex Sōl, an AI-driven tax compliance platform that connects reporting, audit records, and ...

Vertex Sōl is designed to support graduated levels of trust, so tax teams can determine when AI recommends a course of action, assists with the work, or acts within defined controls they set. At every ...